KYMR
Kymera TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The post-earnings bull read is that Q1 reinforced balance-sheet durability and platform breadth: cash, cash equivalents and investments were $1.55 billion at March 31, 2026 with runway into 2029, KT-579 entered Phase 1, and Gilead’s exercised KT-200 option adds a $45 million milestone [#8-K-2026-04-30]. Secondary coverage also framed the quarter as better than expected, with Zacks reporting EPS of -$0.71 versus a -$0.89 consensus and revenue above expectations.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.7.
What can break
KT-579 is only in Phase 1 healthy volunteers, so the program still faces classic early-stage safety, pharmacodynamic, and translation risk [#8-K-2026-04-30].
Momentum
94
Value
41
Sentiment
26
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $90.00 · Bull $115.00 · Bear $62.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $127.05
Why
Momentum94 · Δ7d -2.7
Value41 · Δ7d +0.1
Sentiment26 · Δ7d -2.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
94
26% active weight
Current posture
7d trendSoftening
Δ7d
-2.7
Δ21d
+6.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
26
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.3
Δ21d
-4.5
Why this grade
Composite grade C. Momentum 94.0 / Value 41.1 / Sentiment 26.1
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$9.33B
Beta
2.22
Shares Out
82.26M
P/E (TTM) · Derived
-30.8
P/S (TTM)
132.11
P/FCF (TTM) · Derived
-41.61
Rev YoY
+55.5%
EPS YoY
-13.3%
Gross Margin
+83.9%
Op Margin
-759.7%
Net Debt
-$766.02M
Current Ratio
10.81
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology